Outcomes and quality of life in patients with locally advanced cancers of vulva and vagina.
Not Applicable
- Conditions
- Health Condition 1: C52- Malignant neoplasm of vaginaHealth Condition 2: C519- Malignant neoplasm of vulva, unspecified
- Registration Number
- CTRI/2022/01/039262
- Lead Sponsor
- Tata Memorial Centre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Patients diagnosed with vulvo-vaginal cancer.
2. Patients treated with Radiation+/- chemotherapy +/- surgery from January 1, 2019- December 31, 2023.
Exclusion Criteria
1. Patients with Metastatic disease at the presentation.
2. Incomplete information on the EMR.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To report patterns of relapse and disease outcomes in patients with vulvovaginal cancer treated with radiation (+/- chemotherapy): RFS, DFSTimepoint: 3 Years
- Secondary Outcome Measures
Name Time Method To report on acute and late effect of treatment outcomes using CTCAE.Timepoint: 5 Years;To report on longitudinal QOL using EORTC QLQ C-30 and VU-34 (English, Hindi, Marathi as applicable)Timepoint: 4,8,12,16,20,24,30,36,42,48, 54,60 months;To report outcomes as a function of p16, AKT, PDL-1 expression.Timepoint: 5 Years